WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies, a leading cancer and stem cell development company, today announced that it has been awarded a grant under the Patient Protection and Affordable Care Act. The Company received a grant of $244,479, which was the maximum allocation, to support its preclinical development of anti-cancer drugs that target a fundamental mechanism that drives the growth of 75% of cancers.
